CYP2C19基因多态性与胃食管反流病质子泵抑制剂治疗疗效的关系  

The relationship between CYP2C19 gene polymorphism and therapeutic efficacy of proton pump inhibitors for gastroesophageal reflux disease

作　　者：曹绍华 高学德 张金冉[3] 姬波 CAO Shao-hua;GAO Xue-de;ZHANG Jin-ran;JI Bo(Department of clinical pharmacy,Affiliated Hospital of Yan’an University,716000;Department of Gastroenterology,Zhengzhou Central Hospital,450007;Department of general medicine,Affiliated Hospital of Yan’an University,716000)

机构地区：[1]延安大学附属医院临床药学科,716000 [2]东莞市人民医院药剂科,257091 [3]延安大学附属医院全科医学科,716000

出　　处：《现代消化及介入诊疗》2020年第7期889-892,共4页Modern Interventional Diagnosis and Treatment in Gastroenterology

基　　金：延安大学附属医院科学技术研究发展计划重点项目(2018ZD—01)。

摘　　要：目的研究CYP2C19基因多态性与胃食管反流病质子泵抑制剂(雷贝拉唑)治疗疗效的关系。方法纳入2015年6月至2019年6月于延安大学附属医院收治的112例胃食管反流病患者为对象,均接受CYP2C19基因多态性检测。按照CYP2C19基因分型结果,将入选的患者分为EM组(快代谢型,40例)、IM组(中等代谢型,54例)、PM组(慢代谢型,18例),均接受为期8周的雷贝拉唑治疗。分析三组CYP2C19等位基因出现频率,比较三组治疗前后胃食管反流病问卷调查(GerdQ)评分情况,并观察三组治疗8周后内镜复查结果。结果EM组CYP2C19等位基因出现频率占35.71%,IM组CYP2C19等位基因出现频率占48.21%,PM组CYP2C19等位基因出现频率占16.08%。三组治疗前及治疗后GerdQ评分比较差异均无统计学意义(P>0.05),但三组治疗后GerdQ评分均显著低于治疗前(P<0.05)。EM组、IM组、PM组反流性食管炎患者治疗8周后内镜复查总有效率分别为85.71%、89.28%、88.89%,差异均无统计学意义(P>0.05)。结论CYP2C19基因多态性与胃食管反流病质子泵抑制剂(雷贝拉唑)治疗疗效并无统计学关联,临床应引起重视。Objective To study the relationship between CYP2C19 gene polymorphism and therapeutic efficacy of proton pump inhibitor(rabeprazole)in gastroesophageal reflux disease(GERD).Methods 112 patients with gastroesophageal reflux disease(GERD)admitted to our hospital from June 2015 to June 2019 were enrolled in this study.All patients were tested for CYP2C19 gene polymorphism.According to CYP2C19 genotyping results,the selected patients were divided into EM group(fast metabolic type,40 cases),IM group(moderate metabolic type,54 cases),PM group(slow metabolic type,18 cases),all received rabeprazole treatment for 8 weeks.The occurrence frequency of CYP2C19 allele in the three groups was analyzed,and the Gerd Q scores of the three groups before and after treatment were compared,and the endoscopic review results of the three groups after 8 weeks of treatment were observed.Results The occurrence frequency of CYP2C19 allele in EM group accounted for 35.71%,CYP2C19 allele in IM group accounted for 48.21%,and CYP2C19 allele in PM group accounted for 16.08%.There was no significant difference in Gerd Q scores between the three groups before and after treatment(P>0.05),but the Gerd Q scores after treatment in the three groups were significantly lower than those before treatment(P<0.05).The total effective rates of endoscopic review in EM group,IM group and PM group after 8 weeks of treatment were 85.71%,89.28%and 88.89%,respectively,with no significant difference(P>0.05).Conclusion CYP2 C19 gene polymorphism is not statistically related to the therapeutic effect of proton pump inhibitors(rabeprazole)in gastroesophageal reflux disease,which should be paid more attention in clinical practice.

关 键 词：CYP2C19基因多态性 胃食管反流病 质子泵抑制剂 

分 类 号：R571[医药卫生—消化系统]